NEW YORK (GenomeWeb News) – DxS has received a license from Canadian regulatory authorities to sell its TheraScreen: K-RAS Mutation Kit as a companion diagnostic for Amgen's colorectal cancer therapy panitumumab (Vectibix), the UK-based firm said today.

In addition, Health Canada licensed the assay for broader use as a diagnostic for other anti-EGFR therapies beyond Vectibix.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.